TY - JOUR
T1 - TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy
AU - Knight, Gabriel M.
AU - Clark, Jeffrey
AU - Boike, Justin R.
AU - Maddur, Haripriya
AU - Ganger, Daniel R.
AU - Talwar, Abhinav
AU - Riaz, Ahsun
AU - Desai, Kush
AU - Mouli, Samdeep
AU - Hohlastos, Elias
AU - Garcia Pagan, Juan Carlos
AU - Gabr, Ahmed
AU - Stein, Brady
AU - Lewandowski, Robert
AU - Thornburg, Bartley
AU - Salem, Riad
N1 - Funding Information:
Potential conflict of interest: Dr. Thornburg consults for Gore. Dr. Garcia Pagan consults for Cook, Shionogi, Gore, Vifor, and Boehringer Ingelheim. He received grants from Novartis, Mallinckrodt, and Noorik. Dr. Boike consults and received grants from Gore.
Publisher Copyright:
© 2021 by the American Association for the Study of Liver Diseases.
PY - 2021/11
Y1 - 2021/11
N2 - Background and Aims: Extrahepatic portal vein occlusion (EHPVO) from portal vein thrombosis is a rare condition associated with substantial morbidity and mortality. The purpose of this study is to investigate the efficacy of transjugular intrahepatic portosystemic shunts (TIPS) for the treatment of chronic EHPVO, cavernomatosis, and mesenteric venous thrombosis in adults without cirrhosis who are refractory to standard-of-care therapy. Approach and Results: Thirty-nine patients with chronic EHPVO received TIPS. Laboratory parameters and follow-up were assessed at 1, 3, 6, 12, and 24 months, and every 6 months thereafter. Two hepatologists adjudicated symptom improvement attributable to mesenteric thrombosis and EHPVO before/after TIPS. Kaplan-Meier was used to assess primary and overall TIPS patency, assessing procedural success. Adverse events, radiation exposure, hospital length-of-stay and patency were recorded. Cavernoma was present in 100%, with TIPS being successful in all cases using splenic, mesenteric, and transhepatic approaches. Symptom improvement was noted in 26 of 30 (87%) at 6-month follow-up. Twelve patients (31%) experienced TIPS thrombosis. There were no significant long-term laboratory adverse events or deaths. At 36 months, freedom from primary TIPS thrombosis was 63%; following secondary interventions, overall patency was increased to 81%. Conclusions: TIPS in chronic, noncirrhotic EHPVO with cavernomas and mesenteric venous thrombosis is technically feasible and does not adversely affect liver function. Most patients demonstrate subjective and objective benefit from TIPS. Improvement in patency rates are needed with proper timing of adjuvant anticoagulation.
AB - Background and Aims: Extrahepatic portal vein occlusion (EHPVO) from portal vein thrombosis is a rare condition associated with substantial morbidity and mortality. The purpose of this study is to investigate the efficacy of transjugular intrahepatic portosystemic shunts (TIPS) for the treatment of chronic EHPVO, cavernomatosis, and mesenteric venous thrombosis in adults without cirrhosis who are refractory to standard-of-care therapy. Approach and Results: Thirty-nine patients with chronic EHPVO received TIPS. Laboratory parameters and follow-up were assessed at 1, 3, 6, 12, and 24 months, and every 6 months thereafter. Two hepatologists adjudicated symptom improvement attributable to mesenteric thrombosis and EHPVO before/after TIPS. Kaplan-Meier was used to assess primary and overall TIPS patency, assessing procedural success. Adverse events, radiation exposure, hospital length-of-stay and patency were recorded. Cavernoma was present in 100%, with TIPS being successful in all cases using splenic, mesenteric, and transhepatic approaches. Symptom improvement was noted in 26 of 30 (87%) at 6-month follow-up. Twelve patients (31%) experienced TIPS thrombosis. There were no significant long-term laboratory adverse events or deaths. At 36 months, freedom from primary TIPS thrombosis was 63%; following secondary interventions, overall patency was increased to 81%. Conclusions: TIPS in chronic, noncirrhotic EHPVO with cavernomas and mesenteric venous thrombosis is technically feasible and does not adversely affect liver function. Most patients demonstrate subjective and objective benefit from TIPS. Improvement in patency rates are needed with proper timing of adjuvant anticoagulation.
UR - http://www.scopus.com/inward/record.url?scp=85109357668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109357668&partnerID=8YFLogxK
U2 - 10.1002/hep.31915
DO - 10.1002/hep.31915
M3 - Article
C2 - 34021505
AN - SCOPUS:85109357668
SN - 0270-9139
VL - 74
SP - 2735
EP - 2744
JO - Hepatology
JF - Hepatology
IS - 5
ER -